Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 04, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements on March 28, 2006, involving the SmithKline Beecham Employee Benefit Trust ("the Trust"):
- Shares Sold: 1,005 Ordinary shares were sold on behalf of participants in the SmithKline Beecham Bonus Investment Plan at a price of GBP 15.13.
- Shares Transferred: 1,193 Ordinary shares were transferred from the Trust to participants in the same plan.
Management Commentary and Risks
The Trust is described as a discretionary fund where all non-US employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that Director Mr. J. Heslop holds an interest in the shares held in the fund in the same capacity as other non-US employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b). No other risks, contingencies, or unusual items are discussed in this text.
Investor Verification Checklist
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following the March 28, 2006 transactions.
- Confirm the current share price relative to the GBP 15.13 transaction price mentioned in the filing.
- Review the full composition of the Trust to understand the scope of Director Mr. J. Heslop's indirect interest.